Advertisement

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

David A. Hyman, MD, JD, on Inclusive Shared Savings

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Deborah Collyar: What's In It for Patients?

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Advertisement

Advertisement

Jan

27

Today In Oncology

Leader in Global Cancer Care, Paul E. Goss, MD, PhD, Dies at 70

New Report Shows Colorectal Cancer is Now Leading Cancer Death Among Those Under 50

Pembrolizumab Plus Lenvatinib in Recurrent Gynecologic Clear Cell Carcinoma

Cabozantinib and Temozolomide in Unresectable or Metastatic Leiomyosarcoma

Nutrition Muscle Loss Compromises Survival in Patients With Cervical Cancer Undergoing Chemoradiotherapy

Advertisement

© 2026 HSP News Service, L.L.C.